Trial Profile
Comparison of Twice-Daily Insulin Lispro Low Mixture Versus Once-Daily Basal Insulin Glargine and Once-Daily Prandial Insulin Lispro as Insulin Intensification Strategies in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Glargine and Metformin and/or Pioglitazone.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Insulin neutral protamine lispro/insulin lispro (Primary) ; Insulin glargine; Insulin lispro
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 25 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
- 25 Sep 2013 Primary endpoint 'Proportion-of-glycosylated-haemoglobin' has been met.
- 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.